To further explore whether cIAP2 expression is associated with sorafenib resistance in liver cancer cells, HepG2 cells were transfected with p-cIAP2 to overexpress this protein and their sensitivity to sorafenib were assessed. This evidence concerns the gene BIRC3 and liver cancer.